Abstract
Bispecific antibodies (bsAb) are considered as promising tools for the elimination of disseminated tumour cells in a minimal residual disease situation. The bsAb-mediated recruitment of an immune effector cell in close vicinity of a tumour cell is thought to induce an antitumoural immune response. However, classical bispecific molecules activate only a single class of immune effector cell that may not yield optimal immune responses. We therefore constructed an intact bispecific antibody, BiUII (anti-CD3 × anti-EpCAM), that not only recognizes tumour cells and T lymphocytes with its two binding arms, but also binds and activates Fcγ-receptor positive accessory cells through its Fc-region. We have demonstrated recently that activated accessory cells contribute to the bsAb-induced antitumoural activity. We now analyse this stimulation in more detail and demonstrate here the BiUll-induced upregulation of activation markers like CD83 and CD95 on accessory cells and the induction of neopterin and biopterin synthesis. Experiments with pure cell subpopulations revealed binding of BiUll to CD64+ accessory cells and CD16+ NK cells, but not to CD32+ B lymphocytes. We provide further evidence for the importance of the Fc-region in that this bispecific molecule stimulates Fcγ-R-positive accessory cells to eliminate tumour cells in vitro by direct phagocytosis. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cella M, Scheidegger D, Palmer Lehmann K, Lane P, Lanzavecchia A and Alber G (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 184: 747–752
Clynes R, Tekechi Y, Moroi Y, Houghton A and Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanona. Proc Natl Acad Sci USA 95: 652–656
Czerniecki BJ, Carter C, Rivoltini L, Koski GK, Kim HI, Weng DE, Roros JG, Hijazi YM, Xu S, Rosenberg SA and Cohen PA (1997) Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells. J Immunol 159: 3823–3837
Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dörken B and Pezzutto A (1998) Immunotherapy of B-cell lymphoma with CD3×19 bispecific antibodies: costimulation via CD28 prevents ‘veto’ apoptosis of antibody-targeted cytotoxic T cells. Blood 92: 4750–4757
de Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips J and van Dijk AJ (1995) CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40: 390–396
Fanger MW, Segal DM and Wunderlich JR (1990) Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J 4: 2846–2850
Haagen IA, Geerars AJ, Clark MR and van de Winkel JG (1995) Interaction of human monocyte Fc gamma receptors with rat lgG2b. A new indicator for the Fc gamma Rlla (R-H131) polymorphism. J Immunol 154: 1852–1860
Heo DS, Park JG, Hata K, Day R, Herberman RB and Whiteside TL (1990) Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumour cytotoxicity. Cancer Res 50: 3681–3690
Inaba K and Steinman RM (1984) Resting and sensitized T lymphocytes exhibit distinct stimulatory (antigen-presenting cell) requirements for growth and lymphokine release. J Exp Med 160: 1717
Kerler F, Hültner L, Ziegler I, Katzenmaier G and Bacher A (1990) Analysis of the tetrahydrobiopterin synthesizing system during maturation of murine reticulocytes. J Cell Physiol 142: 268–271
Klein SC, Boer LH, De Weger RA, De Gast GC and Bast EJEG (1997) Release of cytokines and soluble cell surface molecules by PBMC after activation with the bispecific antibody CD3×CD19. Scand J Immunol 46: 452–458
Lindhofer H, Menzel H, Günther W, Hültner L and Thierfelder S (1996) Bispecific antibodies target operationally tumourspecific antigens in two leukemia relapse models. Blood 88: 4651
Lindhofer H, Mocikat R, Steipe B and Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219–225
Mayer B and Hemmens B (1997) Biosynthesis and action of nitric oxide in mammalian cells. Trends Biochem Sci 22: 477–481
McLellan AD, Sorg RV, Williams LA and Hart DN (1996) Human dendritic cells activate T lymphocytes via a CD40:CD40 ligand-dependent pathway. Eur J Immunol 26: 1204–1210
Medvedev AE, Johnsen AC, Haux J, Steinkjer B, Egeberg K, Lynch DH, Sundan A and Espevik T (1997) Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokines 9: 394–404
Quak JJ, Van Dongen G, Brakkee JG, Hayashida DJ, Balm AJ, Snow GB and Meijer CJ (1990) Production of a monoclonal antibody (K 931) to a squamous cell carcinoma associated antigen identified as the 17–1A antigen. Hybridoma 9: 377–387
Ridge JP, Di Rosa F and Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478
Robertson MJ, Manley TJ, Pichert G, Cameron C, Cochran KJ, Levine H and Ritz J (1995) Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma 17: 51–61
Schott K, Guetlich M and Ziegler I (1993) Induction of GTP-cyclohydrolase I mRNA expression by lectin activation and interferon-gamma treatment in human cells associated with the immune response. J Cell Physiol 56: 12–16
Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271–296
Stüber E, Strober W and Neurath M (1996) Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through inhibition of interleukin 12 secretion. J Exp Med 183: 693
Valerius T, Stockmeyer B, vam Spriel A, Graziano R, van den Herik-Oudijk I, Repp R, Deo Y, Lund J, Kalden J, Gramatzki M and van de Winkel JGJ (1997) FcαRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 90: 4485–4492
Van Gool SW, Vandenberghe P, de Boer M and Ceuppens JL (1996) CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 153: 47–83
Weiner LM, Clark JI, Ring DB and Alpaugh RK (1995) Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 4: 453–456
Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P and Garcia de Palazzo I (1993) A human tumour xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53: 94–100
Zeidler R, Reisbach G, Lang S, Wollenberg B, Chaubal S, Schmitt B and Lindhofer H (2000) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol 163: 1246–1252
Zhou LJ and Tedder TF (1996) CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA 93: 2588–2592
Ziegler I (1990) Production of pteridines during hematopoiesis and T-lymphocyte proliferation: Potential participation in the control of cytokine signal transmission. Med Res Rev 10: 95–114
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Zeidler, R., Mysliwietz, J., Csánady, M. et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83, 261–266 (2000). https://doi.org/10.1054/bjoc.2000.1237
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1237
Keywords
This article is cited by
-
Development of a bispecific immune engager using a recombinant malaria protein
Cell Death & Disease (2021)
-
First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity
Cancer Immunology, Immunotherapy (2021)
-
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer
British Journal of Cancer (2018)
-
Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies
BioDrugs (2018)
-
The development of bispecific antibodies and their applications in tumor immune escape
Experimental Hematology & Oncology (2017)